Page last updated: 2024-11-04

tinidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5479
CHEMBL ID1220
CHEBI ID63627
SCHEMBL ID21141
MeSH IDM0021569

Synonyms (188)

Synonym
MLS001146883
HMS3394C09
AB00053176-16
BRD-K89125793-001-05-4
protozol
MLS000069717 ,
DIVK1C_006804
tinidazol [inn-spanish]
cp-12574
pletil
tinidazolum [inn-latin]
simplotan
tricolam
brn 0618182
cp 12574
fasigyn
trimonase
fasigin
cp-12,574
tindamax
1h-imidazole, 1-(2-(ethylsulfonyl)ethyl)-2-methyl-5-nitro-
einecs 243-014-4
bioshik
ccris 7621
imidazole, 1-(2-(ethylsulfonyl)ethyl)-2-methyl-5-nitro-
ethyl (2-(2-methyl-5-nitro-1-imidazolyl)ethyl)sulfone
tinidazol
hsdb 7362
sorquetan
SPECTRUM_001266
PRESTWICK_136
cas-19387-91-8
NCGC00016741-01
BSPBIO_003183
imidazole, 1-(2-(ethylsulfonyl)ethyl)-2-methyl-4-nitro-
fasigyntrade mark
1-[2-(ethylsulfonyl)ethyl]-2-methyl-5-nitro-1h-imidazole
1-(2-ethylsulfonylethyl)-2-methyl-5-nitro-imidazole
tinidazole
tindamaxtrade mark
19387-91-8
simplotantrade mark
BSPBIO_000812
OPREA1_342844
BPBIO1_000894
SPECTRUM5_001715
AB00053176
1-(2-(ethylsulfonyl)ethyl)-2-methyl-5-nitroimidazole
timidazole
DB00911
D01426
tindamax (tn)
tinidazole (jp17/usp/inn)
haisigyn (tn)
NCGC00022212-03
NCGC00022212-04
smr000058194
KBIO2_006882
KBIO2_001746
KBIOSS_001746
KBIO2_004314
KBIOGR_000899
KBIO1_001748
KBIO3_002683
PRESTWICK0_000766
SPECPLUS_000708
SPECTRUM2_000648
SPECTRUM3_001512
SPBIO_000655
PRESTWICK1_000766
SPBIO_002751
SPECTRUM4_000230
SPECTRUM1502127
PRESTWICK2_000766
PRESTWICK3_000766
NCGC00016741-02
NCGC00022212-05
cp12574
HMS2052C09
AC-1618
HMS2092D14
HMS2090B14
haisigyn
nsc-758189
chebi:63627 ,
CHEMBL1220
VU0239922-6
AKOS000747070
HMS1921L06
HMS1570I14
1-(2-ethylsulfonylethyl)-2-methyl-5-nitroimidazole
STK801761
HMS2097I14
amtiba
unii-033kf7v46h
tinidazole [usan:usp:inn:ban:jan]
5-23-05-00067 (beilstein handbook reference)
glongyn
nsc 758189
033kf7v46h ,
A813669
1-[2-(ethylsulfonyl)ethyl]-2-methyl-5-nitroimidazole
BBL010767
pharmakon1600-01502127
nsc758189
MLS001424192
dtxcid003676
dtxsid4023676 ,
tox21_110586
tinidazolum
HMS2231E23
S4068
CCG-39907
NCGC00016741-05
NCGC00016741-06
NCGC00016741-07
NCGC00016741-03
NCGC00016741-04
1-(ethylsulfonyl)-2-(2-methyl-5-nitroimidazolyl)ethane
FT-0675241
tinidazole [hsdb]
tinidazole [mi]
tinidazole [vandf]
tinidazole [orange book]
tinidazole [mart.]
tinidazole [who-dd]
tinidazole [usp-rs]
tinidazole [inn]
tinidazole [usp monograph]
tinidazole [jan]
tinidazole [usan]
tinidazole [ep monograph]
HMS3374P07
HY-B0177
CS-2055
NC00346
SCHEMBL21141
NCGC00016741-09
tox21_110586_1
KS-5180
T3058
1-(2'-(ethylsulfonyl)-ethyl]-2-methyl-5-nitroimidazole
1-(2-(ethylsulfonyl)ethyl)-2-methyl-5-nitro-1h-imidazole
tox21 110586
AB00053176_18
AB00053176_17
OPERA_ID_779
1-[2-(ethanesulfonyl)ethyl]-2-methyl-5-nitro-1h-imidazole
mfcd00057217
SR-01000000210-5
sr-01000000210
tinidazole, vetranal(tm), analytical standard
tinidazole, united states pharmacopeia (usp) reference standard
Z56763819
HMS3652A08
tinidazole, european pharmacopoeia (ep) reference standard
1h-imidazole, 1-[2-(ethylsulfonyl)ethyl]-2-methyl-5-nitro-
SR-01000000210-6
SR-01000000210-3
SBI-0052674.P002
HMS3714I14
1h-imidazole, 1-[2-(ethylsulfonyl)ethyl]-2-methyl-5-nitro-, radical ion(1-)
148159-84-6
SW196447-4
symplotan
bdbm50248360
BCP20694
timtec-bb sbb006917 tinidazole 1-(2-(ethylsulfonyl)ethyl)-2-methyl-5-nitro-1h-imidazol
methyl-5-nitro-1h-imidazole
tinidazole,(s)
1-(2-(ethylsulfonyl)ethyl)-2-
tinidazole 100 microg/ml in acetonitrile
Q1321320
EN300-119371
mcule 2580495783
1-[2-(ethylsulfonyl)ethyl]-2-methyl-5-nitroimidazol
gtpl12341
p01ab02
tinidazole (ep monograph)
j01xd02
tinidazole (usp-rs)
tinidazole (usp monograph)
tinidazole (mart.)
tinidazolo
tindazole
tinidazolum (inn-latin)
tinidazole (usan:usp:inn:ban:jan)
tinidazol (inn-spanish)

Research Excerpts

Overview

Tinidazole (TNZ) is an anti-parasite drug used in the treatment of a variety of amebic and parasitic infections. It is a 5-nitroimidazoles derivative as well as metronidazols but with a longer plasma half-life. Tinidazol appears to be a promising agent for thetreatment of trichomoniasis, giardiasis, amebiasis, and amebi liver abscess.

ExcerptReferenceRelevance
"Tinidazole is a 5-nitroimidazole derivative as well as metronidazole but with a longer plasma half-life."( Tinidazole: Another Therapeutic Option for Syphilis?
Ciccarese, G; Drago, F; Parodi, A; Rebora, A, 2020
)
2.72
"Tinidazole (TNZ) is an anti-parasite drug used in the treatment of a variety of amebic and parasitic infections. "( Formulation and solid state characterization of carboxylic acid-based co-crystals of tinidazole: An approach to enhance solubility.
Awasthi, R; Dagade, RH; Dua, K; Madan, JR,
)
1.8
"Tinidazole is a 5-nitroimidazole approved in the USA for the treatment of indications including amoebiasis and giardiasis."( Triangular test design to evaluate tinidazole in the prevention of Plasmodium vivax relapse.
Cheah, PY; Lwin, KM; Macareo, L; Miller, RS; Nosten, F; Yuentrakul, P, 2013
)
1.39
"Tinidazole is a versatile anti-amoebic and anti-anaerobic drug used in treatment of intestinal infection. "( Development of microbial trigger based oral formulation of Tinidazole and its Gamma Scintigraphy Evaluation: A promising tool against anaerobic microbes associated GI problems.
Bhatnagar, A; Khare, NK; Kumar, N; Nishad, DK; Sharma, BG, 2016
)
2.12
"Tinidazole is a 5-nitroimidazole initially introduced into clinical medicine in 1969 for the treatment of unicellular parasites. "( [Why not revisiting tinidazole as potential treatment of odontogenic infections?].
Aguilar, L; Bascones, A; Gamboa, MS; Giménez, M; Gómez-Lus, ML; Manso, F, 2008
)
2.11
"Tinidazole is a 5-nitroimidazole active in vitro against a wide variety of anaerobic bacteria and protozoa. "( [Tinidazole: a classical anaerobical drug with multiple potential uses nowadays].
Giménez, MJ; Granizo, JJ; Manso, FJ; Pía Rodicio, M, 2009
)
2.71
"Tinidazole appears to be a promising agent for the treatment of trichomoniasis, giardiasis, amebiasis, and amebic liver abscess. "( Tinidazole: a nitroimidazole antiprotozoal agent.
Doan, TL; Fung, HB, 2005
)
3.21
"Tinidazole is a 5-nitroimidazole with selective activity against anaerobic bacteria and protozoa. "( Tinidazole--microbiology, pharmacology and efficacy in anaerobic infections.
Kager, L; Nord, CE,
)
3.02
"Tinidazole is a potent nitroimidazole compound active against, and used to treat, Trichomonas vaginalis infections in males and females. "( Pharmacokinetics of tinidazole in male and female subjects.
Alton, KB; Chaikin, P; Sampson, C; Weintraub, HS,
)
1.9
"Tinidazole is a very promising drug, being effective in single dosage with infrequent side effects."( The treatment of giardiasis.
Mendelson, RM, 1980
)
0.98
"Tinidazole is an antiparasitic drug belonging to the 5-nitroimidazole family. "( Bacterial mutagens in the urine of patients under tinidazole treatment.
de la Torre, RA; Dorado, V; Espinosa-Aguirre, JJ; Hernández, JM; Lares-Asseff, I; Rubino, J; Wong, M, 1996
)
1.99
"Tinidazole is a noteworthy addition to anti-amoebic therapy."( Tinidazole and metronidazole in the treatment of amoebic liver abscess.
Itigi, A; Mathur, SN; Rai, V, 1977
)
2.42

Effects

Tinidazole has been used for vaginal infection worldwide but not in the US for > 40 years. Has been shown to be efficacious in protozoal infections such as trichomonal vaginitis, amoebiasis and giardiasis.

ExcerptReferenceRelevance
"Tinidazole (TIN) has amoebicidal, giardicidal, antifungal, and antimicrobial activities. "( Overview of Analytical Methods for Evaluating Tinidazole.
Kogawa, AC; Pereira Sousa, JC, 2023
)
2.61
"Tinidazole has been used for vaginal infection worldwide but not in the US for > 40 years. "( Tinidazole for the treatment of vaginal infections.
Nailor, MD; Sobel, JD, 2007
)
3.23
"Tinidazole has been used for bacterial vaginosis (BV) outside the USA for almost four decades. "( Tinidazole for bacterial vaginosis.
Nailor, MD; Sobel, JD, 2007
)
3.23
"Tinidazole has been shown to be efficacious in protozoal infections such as trichomonal vaginitis, amoebiasis and giardiasis."( Tinidazole--microbiology, pharmacology and efficacy in anaerobic infections.
Kager, L; Nord, CE,
)
2.3
"Tinidazole has been reported to be highly effective against trichomoniasis, giardiasis and amoebiasis. "( Aspects of the pharmacology and pharmacokinetics of nitroimidazoles with special reference to tinidazole.
Noguchi, Y; Tanaka, T, 1978
)
1.92
"Tinidazole has distinct advantages over metronidazole in the one-dose treatment of trichomonal vaginitis."( Single-dose oral treatment of vaginal trichomoniasis with tinidazole and metronidazole.
Manorama, HT; Shenoy, DR, 1978
)
1.22
"Tinidazole also has activity against some Gram-negative anaerobic bacilli, including Bacteroides spp."( Tinidazole: a review of its antiprotozoal activity and therapeutic efficacy.
Avery, GS; Brogden, RN; Pinder, RM; Sawyer, PR; Speight, TM, 1976
)
2.42

Actions

ExcerptReferenceRelevance
"Tinidazole at lower dose offers a better efficacy than metronidazole in long-term cure rates and in preventing relapses with better side effect profile."( Randomized, double-blind, comparative study of oral metronidazole and tinidazole in treatment of bacterial vaginosis.
Basavareddy, A; Meher, BR; Mukherjee, D; Raja, IM,
)
1.81

Treatment

Treatment of tinidazole with a mixture of hydrogen peroxide and acetic acid, or liver homogenate preparations, yields the N-3 oxide.

ExcerptReferenceRelevance
"All tinidazole-treated patients had clinically effective blood concentrations of the drug at the time of the operation."( Tinidazole as preventive treatment in elective colonic surgery.
Gnarpe, H; Persson, S, 1981
)
2.19
"Treatment of tinidazole with a mixture of hydrogen peroxide and acetic acid, or liver homogenate preparations, yields the N-3 oxide. "( N-oxidation: a possible route of tinidazole metabolism in man.
Coker, HA; Edoho, EJ; Essien, EE, 1990
)
0.93

Toxicity

Levofloxacin-tinidazole-based triple therapy was highly effective and safe as a first-line regimen in Indian patients with gastroduodenal ulcer disease associated with H.I.V. Teratogenicity tests in animals have given negative results in the case of metronidazoles.

ExcerptReferenceRelevance
" Teratogenicity tests in animals have given negative results in the case of metronidazole, ornidazole and tinidazole, and in the case of metronidazole no evidence of any adverse effect on the outcome of pregnancy was seen in women treated for trichomoniasis at various times during gestation, including the first trimester."( Safety of nitroimidazoles.
Roe, FJ, 1985
)
0.48
" The use of such therapies, however, may be impeded by a number of major disadvantages, including reduced patient compliance, the incidence of adverse events and primary or acquired antibiotic resistance."( Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment.
Malfertheiner, P, 1993
)
0.29
" In conclusion, the pharmacological profile of the aforementioned combination in the dosages employed in mice, rats, guinea-pigs, rabbits and dogs shows that it is safe and well tolerated."( Safety pharmacology of a combination of tinidazole and oxyphenonium bromide.
Bhatt, A; David, J; Joseph, T; Nagarani, A; Vaidya, A; Venkataraman, V, 1997
)
0.56
" Twenty-four patients experienced side-effects, but in only seven cases was treatment discontinued due to adverse events."( Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate.
Bazzoli, F; Cannizzaro, O; D'Angelo, A; Ederle, A; Fossi, S; Gerace, G; Iaquinto, G; Olivieri, A; Pozzato, P; Reina, G; Ricciardiello, L; Roda, E; Scarpulla, G; Spadaccini, A; Tosatto, R; Zagari, M, 1998
)
0.3
" Three novel RBC-based triple therapies proved to be safe and well tolerated, with discontinuations due to side-effects occurring in less than 5% of cases."( Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate.
Bazzoli, F; Cannizzaro, O; D'Angelo, A; Ederle, A; Fossi, S; Gerace, G; Iaquinto, G; Olivieri, A; Pozzato, P; Reina, G; Ricciardiello, L; Roda, E; Scarpulla, G; Spadaccini, A; Tosatto, R; Zagari, M, 1998
)
0.3
" The mtk-QSTR model was based on artificial neural networks (ANN), allowing the classification of compounds as toxic or non-toxic."( In silico assessment of the acute toxicity of chemicals: recent advances and new model for multitasking prediction of toxic effect.
Cordeiro, MN; Kleandrova, VV; Luan, F; Speck-Planche, A, 2015
)
0.42

Pharmacokinetics

Pharmacokinetic profiles, including area under the curve from time zero to infinity (AUC0-inf), peak plasma concentration (Cmax), time to reach Cmax (tmax), oral clearance (CL/F), elimination rate constant (Ke), and elimination half-life (t1/2), were determined following a single oral dose of tinidazole.

ExcerptReferenceRelevance
" These pharmacokinetic differences result from the longer half-life of tinidazole."( Aspects of the pharmacology and pharmacokinetics of nitroimidazoles with special reference to tinidazole.
Noguchi, Y; Tanaka, T, 1978
)
0.71
" The longer half-life of tinidazole led to significantly higher serum concentrations (by bioassay and chemical assay) of tinidazole than of metronidazole from 6 hrs onwards."( Pharmacokinetics of tinidazole and metronidazole in women after single large oral doses.
Monro, AM; Wood, BA, 1975
)
0.88
" The apparent total plasma clearance of the drug was about twofold higher in dogs than in cats, resulting in an elimination half-life that was twice as long in cats (8."( Pharmacokinetics of tinidazole in dogs and cats.
Järvinen, A; Mero, M; Sarkiala, E; Välttilä, S, 1991
)
0.6
" The mean pharmacokinetic parameters obtained for tinidazole were similar to those reported in the literature; total clearance 51 ml/min, renal clearance 10 ml/min, volume of distribution 501 and half-life 11."( Pharmacokinetics and metabolism of 14C-tinidazole in humans.
Baker, JM; Brodie, RR; Chasseaud, LF; Darragh, A; Faulkner, JK; John, BA; Lambe, RF; Wood, BA; Wood, SG, 1986
)
0.79
"The pharmacokinetic properties of metronidazole (M) and tinidazole (T) were studied in patients undergoing colorectal surgery after a single preoperative dose of 1500 mg infused during 50 minutes."( Comparative pharmacokinetics of metronidazole and tinidazole used as single dose prophylactic agents.
Bakkevold, K; Bergan, T; Leinebø, O; Salvesen, B; Søreide, O; Ulvik, NM, 1984
)
0.77
" After intravenous administration the mean elimination half-life of tinidazole was 17."( Tinidazole pharmacokinetics in severe renal failure.
Bailey, RR; Robson, RA; Sharman, JR,
)
1.81
" Whenever the parameters were calculable, the elimination half-life of tinidazole (range of means, 14."( Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route.
Lamminsivu, U; Männistö, PT; Mäntylä, R; Mattila, J; Nykänen, S, 1983
)
0.75
" Tinidazole elimination plasma half-life was 15."( Pharmacokinetics of tinidazole in chronic renal failure and in patients on haemodialysis.
Chevalier, GC; Dubois, DM; Flouvat, BL; Humbert, G; Imbert, C; Roux, AF; Temperville, BP, 1983
)
1.5
" Speculation exists in the literature that observed differences in tinidazole plasma concentrations between males and females may be due to sex-mediated pharmacokinetic differences."( Pharmacokinetics of tinidazole in male and female subjects.
Alton, KB; Chaikin, P; Sampson, C; Weintraub, HS,
)
0.69
" Terminal half-life was 394 minutes after IV administration and 524 minutes (harmonic mean) after oral administration."( Pharmacokinetics of single-dose administration of tinidazole in unweaned calves.
Nokelainen, M; Pyörälä, S; Rainio, V; Silvennoinen, P; Soback, S, 1994
)
0.54
" The method is simple, sensitive and has been successfully used in a pharmacokinetic study conducted in healthy human volunteers."( Validated HPLC method for the determination of tinidazole in human serum and its application in a clinical pharmacokinetic study.
Alapati, VR; Chaluvadi, MR; Jayasagar, G; Krishna, DR; Mada, SR; Rajnarayana, K, 2002
)
0.57
" The pharmacokinetic parameters were calculated from the plasma concentration of tinidazole versus time data."( Pharmacokinetic evaluation of guar gum-based colon-targeted drug delivery systems of tinidazole in healthy human volunteers.
Bhaskar, P; Krishnaiah, YS; Latha, K; Muzib, YI; Satyanarayana, V,
)
0.58
" This method has been successfully applied to the pharmacokinetic study of ONZ and TNZ in rabbit blood."( In vivo and real time determination of ornidazole and tinidazole and pharmacokinetic study by capillary electrophoresis with microdialysis.
Wu, K; Zhang, L; Zhang, Z, 2006
)
0.58
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"Pharmacokinetic profiles, including area under the curve from time zero to infinity (AUC0-inf), peak plasma concentration (Cmax), time to reach Cmax (tmax), oral clearance (CL/F), elimination rate constant (Ke), and elimination half-life (t1/2), were determined following a single oral dose of tinidazole."( Pharmacokinetics of Tinidazole in Chinese subjects: comparison of Mongolian, Korean, Hui, Uighur and Han nationalities.
Chang, XY; Guo, T; Xia, DY, 2009
)
0.85
" The validated method was applied for the analysis of in vivo pharmacokinetic (PK) study samples after intravenous administration of MTZ to a rat."( Dried blood spot assay for estimation of metronidazole concentrations in rats and its application in single animal drug pharmacokinetic study.
Donnelly, RF; Garland, MJ; Kole, PL; Majithia, R; McElnay, J; Migalska, K; Singh, TR, 2011
)
0.37
" It has been successfully applied to the pharmacokinetic research of a film-forming solution in rat."( Development of a HPLC/MS/MS method for simultaneous determination of tinidazole, dyclonine and chlorhexidine in rat plasma and its application in the pharmacokinetic research of a film-forming solution.
Hou, Y; Liu, J; Wu, L; Zhang, Y, 2012
)
0.61
" The validated method was applied to assay real plasma samples used for pharmacokinetic studies and therapeutic drug monitoring of the selected drugs."( Simultaneous quantification of linezolid, tinidazole, norfloxacin, moxifloxacin, levofloxacin, and gatifloxacin in human plasma for therapeutic drug monitoring and pharmacokinetic studies in human volunteers.
Helmy, SA, 2013
)
0.65
"This assay method was valid within a wide range of plasma concentrations and may be proposed as a suitable method for pharmacokinetic studies, therapeutic drug monitoring implementation, and routine clinical applications, especially for some populations of patients who receive a combination of these drugs."( Simultaneous quantification of linezolid, tinidazole, norfloxacin, moxifloxacin, levofloxacin, and gatifloxacin in human plasma for therapeutic drug monitoring and pharmacokinetic studies in human volunteers.
Helmy, SA, 2013
)
0.65
"After single intravenous doses of 25, 50 and 100mg/kg brazilin in rats, the main PK parameters were as follows: Cmax were 18."( A simple high-performance liquid chromatographic method for the determination of brazilin and its application to a pharmacokinetic study in rats.
Ai-dong, W; Fang, D; Jinyi, Z; Yan, L; Yan-yan, J; Ying, S; Yuan, S, 2014
)
0.4
"It showed that the brazilin was eliminated moderately in rat by intravenous injection route with t1/2 of 6h and showed a dose-dependence profile of Cmax and AUC0-24 at the doses of 25~100mg/kg of brazilin for injection in rats."( A simple high-performance liquid chromatographic method for the determination of brazilin and its application to a pharmacokinetic study in rats.
Ai-dong, W; Fang, D; Jinyi, Z; Yan, L; Yan-yan, J; Ying, S; Yuan, S, 2014
)
0.4
"This study represents simple inexpensive chromatographic determination of ciprofloxacin (CIP) and tinidazole (TIN) simultaneously in human plasma using HPLC-DAD followed by a pharmacokinetic application."( Sensitive inexpensive chromatographic determination of an antimicrobial combination in human plasma and its pharmacokinetic application.
Abdel Moneim, MM; Belal, SF; El-Kimary, EI; Khamis, EF, 2018
)
0.7

Compound-Compound Interactions

Two-week courses of either high-dose famotidine or omeprazole, both combined with amoxycillin and tinidazole, are equally effective for eradication of H. pylori-related gastritis.

ExcerptReferenceRelevance
"The purpose of this study is to evaluate and compare the clinical and radiographic effectiveness of Ciprofloxacin, Minocycline, Metronidazole combination with Ciprofloxacin, Minocycline and Tinidazole combination when used for Lesion Sterilization and Tissue Repair in primary teeth."( In vivo evaluation of lesion sterilization and tissue repair in primary teeth pulp therapy using two antibiotic drug combinations.
Anantharaj, A; Jaya, AR; Praveen, P; Rani, PS; Venkataraghavan, K, 2012
)
0.57
"Purpose: To investigate the therapeutic effects of minocycline combined with tinidazole in the treatment of chronic periodontitis (CP)."( Effects Of Minocycline Combined With Tinidazole For Treatment Of Chronic Periodontitis.
Gu, J; Huang, J; Xue, J, 2021
)
1.12
" Clarithromycin combined with tinidazole can effectively improve the clinical effect of Helicobacter pylori-related gastritis and reduce the expression level of COX-2."( Clinical Effect of Clarithromycin Combined with Tinidazole on Helicobacter pylori-Related Gastritis and Its Influence on COX-2 Expression.
He, C; Kong, F; Liu, Y; Wang, K; Zhao, W; Zhu, X, 2021
)
1.17

Bioavailability

In human adults, tinidazole had a bioavailability of 100% and a V(d) of 50. The delayed Tmax, decreased Cmax, and Ka, indicated that the drug was not released in the stomach and small intestine but delivered to the colon.

ExcerptReferenceRelevance
"1 h and the bioavailability essentially 100%."( Pharmacokinetics of tinidazole in the horse.
Hänninen, U; Kaartinen, L; Kotilainen, T; Mero, M; Pyörälä, S; Silvennoinen, P, 1990
)
0.6
" The bioavailability of oral doses of metronidazole is 88-95%, that of tinidazole 90%."( Antibacterial activity and pharmacokinetics of nitroimidazoles. A review.
Bergan, T, 1985
)
0.5
" The bioavailability of single oral doses ranged between 88 and 129% with a mean of 99%."( Biological availability and pharmacokinetics of tinidazole after single and repeated doses.
Andersson, KE; Ando, G; Lunell, E; Vinge, E, 1983
)
0.52
" Bioavailability of either drug, calculated according to the formula (area under the curve for oral administration)/(area under the curve for infusion), was practically complete after oral administration and was poorer after rectal and especially vaginal administration."( Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route.
Lamminsivu, U; Männistö, PT; Mäntylä, R; Mattila, J; Nykänen, S, 1983
)
0.52
" Bioavailability was 99."( Pharmacokinetics of single-dose administration of tinidazole in unweaned calves.
Nokelainen, M; Pyörälä, S; Rainio, V; Silvennoinen, P; Soback, S, 1994
)
0.54
" The delayed Tmax, decreased Cmax, and Ka, and unaltered bioavailability and elimination half-life of tinidazole from guar gum-based colon-targeted tinidazole tablets, in comparison with the immediate tablets, indicated that the drug was not released in the stomach and small intestine but delivered to the colon."( Pharmacokinetic evaluation of guar gum-based colon-targeted drug delivery systems of tinidazole in healthy human volunteers.
Bhaskar, P; Krishnaiah, YS; Latha, K; Muzib, YI; Satyanarayana, V,
)
0.57
" In human adults, tinidazole had a bioavailability of 100% and a V(d) of 50."( Tinidazole: a nitroimidazole antiprotozoal agent.
Doan, TL; Fung, HB, 2005
)
2.1
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"An early prediction of solubility in physiological media (PBS, SGF and SIF) is useful to predict qualitatively bioavailability and absorption of lead candidates."( Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
Bharate, SS; Vishwakarma, RA, 2015
)
0.42
" Dugs' plasma levels were followed for 12 or 72 h post dosing for CIP and TIN, respectively, and different PK data for the two drugs were calculated and they were comparable to the reported values demonstrating successful future application of the presented method in PK, bioequivalence and bioavailability studies."( Sensitive inexpensive chromatographic determination of an antimicrobial combination in human plasma and its pharmacokinetic application.
Abdel Moneim, MM; Belal, SF; El-Kimary, EI; Khamis, EF, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Tinidazole was administered to healthy volunteers and serum concentrations were measured following single oral and intravenous doses. Treatment regimens varied: 20% received single 2-g dosing, 50% received high-dose regimens. In view of the in-vitro sensitivities of various anaerobic bacteria, a dosage of 10-15 mg/kg of tinidzole, o

ExcerptRelevanceReference
" The patients were divided in two groups: Group I, composed of 50 patients were divided with a dosage of 300 mgm per day for seven consecutive days."( [New derivative of nitromidazole-tinidazole, for the treatment of giardiasis].
Huggins, D,
)
0.41
" However, in 7 cases the dosage had to be repeated."( Amoebic liver abscess and clinical experiences with tinidazole in Bangladesh.
Islam, N; Quaderi, MA; Rahman, A; Rahman, MS, 1978
)
0.51
" Either dosage of tinidazole initially cleared all stool samples of Giardia lamblia, and most clinical and parasitological failures were first detected a few weeks after the treatment."( Comparative evaluation of two dosages of tinidazole in the treatment of giardiasis.
Jokipii, AM; Jokipii, L, 1978
)
0.86
" Current treatment of trichomoniasis in the United States is with metronidazole, which in repeated or increased dosage can often overcome the organism's resistance to the drug."( Trichomoniasis: trends in diagnosis and management.
Kent, HL; Lossick, JG, 1991
)
0.28
" In cases of repeated failure, the authors prescribed a dosage of 500 mg of diloxanide furoate three times per day (TID) for 10 days."( Treatment of asymptomatic amebiasis in homosexual men. Clinical trials with metronidazole, tinidazole, and diloxanide furoate.
Bergström, T; Håkansson, C; Johanisson, G; Norkrans, G; Thorén, K,
)
0.35
" In view of the in-vitro sensitivities of various anaerobic bacteria, a dosage of 10-15 mg/kg of tinidazole, orally, at 12-h intervals, can be recommended for the treatment of anaerobic infections in horses."( Pharmacokinetics of tinidazole in the horse.
Hänninen, U; Kaartinen, L; Kotilainen, T; Mero, M; Pyörälä, S; Silvennoinen, P, 1990
)
0.82
"Efficacity of tiniba (tinidasole, Kadila, India) and of fasigyn (Polfa, Poland) dosed 300 mg daily for 7 days was 87."( [Comparative efficacy of tiniba and fasigyn in treating primary and persisting Giardia infections].
Firsova, RA; Kulinich, GV; Ozeretskovskaia, NN; Panteleeva, EA,
)
0.13
" fragilis was similar and at all dosage levels a significant correlation was found between the numbers of Bact."( Quantification of the effect of anti-anaerobic drugs in experimental Bacteroides fragilis infection in mice.
Dijkmans, BA; Hermans, J; Mattie, H; van Furth, R, 1984
)
0.27
" In addition, the efficacy of 1-day tinidazole prophylaxis with 8- and 12-h dosage intervals in the prevention of postoperative infection complications was evaluated."( Tinidazole prophylaxis in elective colorectal surgery.
Kairaluoma, MI; Laitinen, S; Ståhlberg, M, 1984
)
1.99
"Tinidazole was administered to healthy volunteers and serum concentrations were measured following single oral and intravenous doses and after repeated dosage at different dose levels."( Biological availability and pharmacokinetics of tinidazole after single and repeated doses.
Andersson, KE; Ando, G; Lunell, E; Vinge, E, 1983
)
1.96
" We cannot, therefore, recommend tinidazole alone in this dosage as a treatment for non-invasive amoebiasis."( Treatment of non-invasive amoebiasis. A comparison between tinidazole alone and in combination with diloxanide furoate.
Bengtsson, E; Pehrson, P, 1983
)
0.79
" In the presence of renal failure no modification of tinidazole dosage would appear to be necessary."( Tinidazole pharmacokinetics in severe renal failure.
Bailey, RR; Robson, RA; Sharman, JR,
)
1.82
"Concentrations of metronidazole and tinidazole in serum and abdominal tissues were determined after a single 500-mg intravenous infusion or after a 5-day oral dosage of 500 mg three times daily in groups of 10 patients each."( Concentrations of metronidazole and tinidazole in abdominal tissues after a single intravenous infusion and repetitive oral administration.
Auvinen, O; Haataja, H; Männistö, P; Tunturi, T; Viitanen, J, 1984
)
0.82
" The prophylactic regimens significantly reduced the infectious complications, as evidenced by fewer infections, less total antibiotic dosage and shorter hospitalization."( Short term chemotherapeutic prophylaxis in gastrointestinal operations.
Bergan, T; Christiansen, E; Fuglesang, J; Giercksky, KE; Johnson, JA, 1980
)
0.26
" Tinidazole is a very promising drug, being effective in single dosage with infrequent side effects."( The treatment of giardiasis.
Mendelson, RM, 1980
)
1.17
" Although the dosage of omeprazole in pediatric patients has not been established (no pediatric formulation exists), clarithromycin is available for use in pediatric patients."( Guidelines for the treatment of Helicobacter pylori in the pediatric population.
Abdel-Rahman, SM; Nahata, MC; Robinson, DM, 1997
)
0.3
" dosing schedule: RBC 400 mg plus clarithromycin 250 mg and tinidazole 500 mg (RBCCT): RBC 400 mg plus clarithromycin 500 mg and amoxycillin 1 g (RBCCA); RBC 400 mg plus tinidazole 500 mg and amoxycillin 1 g (RBCTA)."( Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate.
Bazzoli, F; Cannizzaro, O; D'Angelo, A; Ederle, A; Fossi, S; Gerace, G; Iaquinto, G; Olivieri, A; Pozzato, P; Reina, G; Ricciardiello, L; Roda, E; Scarpulla, G; Spadaccini, A; Tosatto, R; Zagari, M, 1998
)
0.54
" pylori eradication rate with a standard triple therapy regardless of the regimen utilized, the dosage and/or the duration of the therapy used appearing not to be sufficient to eradicate the infection efficiently."( Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus.
Armuzzi, A; Gasbarrini, A; Gasbarrini, G; Ghirlanda, G; Ojetti, V; Pitocco, D; Pola, P; Silveri, NG, 2000
)
0.31
" The recommended dosage of tinidazole is a single dose of 2 g for trichomoniasis and giardiasis, and 2 g/d for 3 to 5 days for amebiasis."( Tinidazole: a nitroimidazole antiprotozoal agent.
Doan, TL; Fung, HB, 2005
)
2.07
" The developed method was successfully applied to the pharmacokinetic and bioequivalence studies between test and reference secnidazole tablets following a single 500 mg oral dosage to 20 healthy volunteers of both genders."( Determination of secnidazole in human plasma by high-performance liquid chromatography with UV detection and its application to the bioequivalence studies.
Gu, Y; Li, X; Ren, H; Sun, J; Wang, G; Xie, H; Yan, B; Zheng, Y, 2007
)
0.34
"0% were obtained with a considerable degree of accuracy when the suggested methods were applied to analysis of synthetic binary mixtures, some commercial dosage forms such as tablets and oral suspension without interference from the commonly encountered excipients and additives."( Determination of two antibacterial binary mixtures by chemometrics-assisted spectrophotometry.
Abdelmageed, OH; Mohamed, Ael-M; Refaat, IH,
)
0.13
" Results obtained showed that, at appropriate concentrations, H(2)O(2) accelerates MNZ degradation by generating additional HO(); however, when the dosage of H(2)O(2) exceeds the optimal concentration, the efficacy of MNZ degradation is reduced."( Gamma irradiation of pharmaceutical compounds, nitroimidazoles, as a new alternative for water treatment.
Ferro-García, MA; López-Peñalver, J; Prados-Joya, G; Rivera-Utrilla, J; Sánchez-Polo, M, 2009
)
0.35
"There were no differences in cure rates between metronidazole and either of the tinidazole dosing regimens that were studied."( Tinidazole vs metronidazole for the treatment of bacterial vaginosis.
Desmond, RA; Schwebke, JR, 2011
)
2.04
" The specificity of the developed methods is investigated by analyzing laboratory prepared mixtures of the three drugs and their combined dosage form."( Comparative study of novel spectrophotometric methods manipulating ratio spectra: an application on pharmaceutical ternary mixture of omeprazole, tinidazole and clarithromycin.
Abdel-Monem Hagazy, M; Lotfy, HM, 2012
)
0.58
"Micellar high-performance liquid chromatography (HPLC) and first-derivative ultraviolet spectrophotometry were used to simultaneously determine fluconazole (FLZ) and tinidazole (TNZ) in combined pharmaceutical dosage forms."( Micellar HPLC and derivative spectrophotometric methods for the simultaneous determination of fluconazole and tinidazole in pharmaceuticals and biological fluids.
Belal, F; Eid, MI; El-Gamal, RM; Sharaf El-Din, MK, 2014
)
0.81
" The study was designed to have a 5% type 1 error and 90% power to show whether tinidazole would produce a relapse rate of less than 20% or greater than 45% through Day 63 of weekly follow-up after initiation of treatment and initial parasite clearance with 3 days of an oral weight based dosing of chloroquine and five days of 2 grams/day of tinidazole."( Triangular test design to evaluate tinidazole in the prevention of Plasmodium vivax relapse.
Cheah, PY; Lwin, KM; Macareo, L; Miller, RS; Nosten, F; Yuentrakul, P, 2013
)
0.89
" In the microchip, the functionality of integrated concentration gradient generator (CGG) with micro-scale cell culture enables dose-response experiment to be performed in a simple and reagent-saving way."( An integrated microfludic device for culturing and screening of Giardia lamblia.
Li, YJ; Wang, YH; Wei, JF; Yang, YS; Zeng, SR; Zhang, XM; Zheng, GX, 2014
)
0.4
" All samples underwent visual and physical inspection for labeling and packaging before physico-chemical quality testing and evaluated based on individual monographs in Pharmacopoeias for identification, assay/content, dosage uniformity, dissolution, disintegration and friability."( Quality of medicines commonly used in the treatment of soil transmitted helminths and giardia in ethiopia: a nationwide survey.
D'Hondt, M; De Spiegeleer, B; Deti, H; Duchateau, L; Levecke, B; Mekonnen, Z; Suleman, S; Vercruysse, J; Wynendaele, E; Zeleke, G, 2014
)
0.4
" The method was successfully applied for determination of both drugs in pharmaceutical dosage forms and real human plasma."( Multiobjective optimization strategy based on desirability functions used for the microemulsion liquid chromatographic separation and quantification of norfloxacin and tinidazole in plasma and formulations.
Abou-Taleb, NH; El-Ashry, SM; El-Sherbiny, DT; El-Wasseef, DR, 2015
)
0.61
" Treatment regimens varied: 20% received single 2-g dosing of either metronidazole or tinidazole, 50% received high-dose regimens, 20% received therapy with vaginal paromomycin, and 10% underwent desensitization for nitroimidazole allergy."( Trichomonas vaginalis Infection in a Tertiary Care Vaginitis Center.
Keating, MA; Nyirjesy, P, 2015
)
0.64
" Dugs' plasma levels were followed for 12 or 72 h post dosing for CIP and TIN, respectively, and different PK data for the two drugs were calculated and they were comparable to the reported values demonstrating successful future application of the presented method in PK, bioequivalence and bioavailability studies."( Sensitive inexpensive chromatographic determination of an antimicrobial combination in human plasma and its pharmacokinetic application.
Abdel Moneim, MM; Belal, SF; El-Kimary, EI; Khamis, EF, 2018
)
0.48
" The efficacy of MMF as an immunosuppressant and long-term safety in cats of this dosage regimen is unknown."(
Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019
)
0.51
" The proposed method was successfully applied for the determination of both drugs in tablets dosage form without interference from the commonly encountered excipients."( Digitally enhanced thin layer chromatography for simultaneous determination of norfloxacin and tinidazole with the aid of Taguchi orthogonal array and desirability function approach: Greenness assessment by analytical Eco-Scale.
Hemdan Abou-Taleb, N; Ibrahim El-Subbagh, H; Mahmoud El-Enany, N; Tawfik El-Sherbiny, D, 2020
)
0.78
" Statistical comparisons of predictive abilities of proposed models against classical least squares CLS model and against each other was performed; whether for analysis of test set mixtures or dosage form."( Partial least squares and linear support vector regression chemometric models for analysis of Norfloxacin and Tinidazole with Tinidazole impurity.
Abdelaleem, EA; Ali, NW; Gamal, M; Hassan, ES; Naguib, IA, 2020
)
0.77
"A sensitive and selective method needs to be developed and validated for simultaneous determination of four drugs (amoxacillin, tinidazole, naproxen and lansoprazole), used for treating Helicobacter pylori infection, in their combined dosage forms."( RP-HPLC-DAD Method Development and Validation for Simultaneous Determination of Lansoprazole, Tinidazole, Amoxicillin, and Naproxen in Their Raw Materials and Combined Dosage Form: DOE Approach for Optimization of the Proposed Method.
Hassib, ST; Mostafa, EA; Sharf, MG; Taha, EA, 2022
)
1.15
"The method can be easily implemented in QC studies of the cited drugs in their dosage forms."( RP-HPLC-DAD Method Development and Validation for Simultaneous Determination of Lansoprazole, Tinidazole, Amoxicillin, and Naproxen in Their Raw Materials and Combined Dosage Form: DOE Approach for Optimization of the Proposed Method.
Hassib, ST; Mostafa, EA; Sharf, MG; Taha, EA, 2022
)
0.94
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antiprotozoal drugAny antimicrobial drug which is used to treat or prevent protozoal infections.
antibacterial drugA drug used to treat or prevent bacterial infections.
antiparasitic agentA substance used to treat or prevent parasitic infections.
antiamoebic agentAn antiparasitic agent which is effective against amoeba, a genus of single-celled amoeboids in the family Amoebidae.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
imidazolesA five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GALC proteinHomo sapiens (human)Potency0.707928.183828.183828.1838AID1159614
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency8.91250.28189.721235.4813AID2326
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency13.33320.001530.607315,848.9004AID1224841
estrogen nuclear receptor alphaHomo sapiens (human)Potency7.55440.000229.305416,493.5996AID743075; AID743077; AID743079
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency11.22020.10009.191631.6228AID1346983
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency7.94330.01789.637444.6684AID588834
survival motor neuron protein isoform dHomo sapiens (human)Potency1.77830.125912.234435.4813AID1458
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency17.78280.00419.962528.1838AID2675
lamin isoform A-delta10Homo sapiens (human)Potency1.99530.891312.067628.1838AID1487
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency3.98110.009610.525035.4813AID1479145
TAR DNA-binding protein 43Homo sapiens (human)Potency39.81071.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (58)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (33)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (27)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (178)

Assay IDTitleYearJournalArticle
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID571174Antimicrobial activity against Clostridium difficile harboring other ribotypes by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID172616The amount of the unchanged form of compound detected in the urine samples collected at 0-18 hr after the treatment by HPLC technique1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID1456705Half life in plasma (unknown origin)2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID16041Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
The influence of physicochemical parameters on the biliary excretion of a series of nitroimidazoles.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID194145The total 54 h urinary excretion of unchanged compound reported as log (percent X 10) of the administered dose1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID26535Capacity factor (log k')1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID172622The amount of unchanged compound in urine collected at 0-72 h after treatment1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID1743047Antigiardial activity against Giardia duodenalis Ec2 incubated for 3 days by fluorescence method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Anti-
AID1146194Antimicrobial activity against Streptococcus pyogenes C 203 by microtitre method1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and biological activity of new 2-nitroimidazole derivatives.
AID1146196Antimicrobial activity against Mycoplasma gallisepticum S6 Weybridge by broth dilution method1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and biological activity of new 2-nitroimidazole derivatives.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID571173Antimicrobial activity against Clostridium difficile harboring ribotype 001 by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID16036Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
The influence of physicochemical parameters on the biliary excretion of a series of nitroimidazoles.
AID1135604Antimicrobial activity against Entamoeba histolytica NIH 200-mu cecal forms infected in Wistar albino rat assessed as cure rate administered qd for 5 days by microscopic analysis1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Bisamidines of 2,6-diaminoanthraquinone as antiamebic agents.
AID1456706Antiparasitic activity against Trichomonas vaginalis clinical isolate after 48 hrs under aerobic conditions by inverted phase contrast microscopic analysis2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases.
AID1193498Thermodynamic equilibrium solubility, log S of the compound simulated gastric fluid at pH 1.2 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1146201Therapeutic index, ratio of LD50 for po dosed mouse to ED50 for Trichomonas vaginalis infected in po dosed mouse1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and biological activity of new 2-nitroimidazole derivatives.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1193497Thermodynamic equilibrium solubility, log S of the compound PBS at pH 7.4 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1146200Acute toxicity in po dosed mouse1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and biological activity of new 2-nitroimidazole derivatives.
AID1193492Thermodynamic equilibrium solubility, log S of the compound in water at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID23240Partition coefficient (logP)1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
The influence of physicochemical parameters on the biliary excretion of a series of nitroimidazoles.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1146197Antimicrobial activity against Trichomonas vaginalis by broth dilution method1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and biological activity of new 2-nitroimidazole derivatives.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1146193Antimicrobial activity against Staphylococcus aureus Tour by microtitre method1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and biological activity of new 2-nitroimidazole derivatives.
AID172618The amount of unchanged compound detected in urine collected at 0-18 hr after treatment1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID1193493Thermodynamic equilibrium solubility, log S of the compound in PBS at pH 7.4 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID16037Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
The influence of physicochemical parameters on the biliary excretion of a series of nitroimidazoles.
AID1743045Antigiardial activity against Giardia duodenalis Ac2 incubated for 3 days by fluorescence method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Anti-
AID1193494Thermodynamic equilibrium solubility, log S of the compound in simulated gastric fluid at pH 1.2 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1743046Antigiardial activity against Giardia duodenalis Ec1 incubated for 3 days by fluorescence method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Anti-
AID1193499Thermodynamic equilibrium solubility, log S of the compound simulated intestinal fluid at pH 6.8 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1743048Antigiardial activity against Giardia lamblia WB (ATCC 30957) incubated for 3 days by [3H]thymidine incorporation based assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Anti-
AID571172Antimicrobial activity against Clostridium difficile harboring ribotype 027 by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID341089Antimicrobial activity against Clostridium difficile clinical isolates by agar dilution method2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.
AID1456722In vivo antibacterial activity against Helicobacter pylori infected in human administered bid for 7 days measured after 30 days post start of the treatment by endoscopic analysis2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1743039Antigiardial activity against Giardia duodenalis GS/M-83-H7 (ATCC 50581) incubated for 3 days by fluorescence method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Anti-
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1456703In vivo antiparasitic activity against Giardia lamblia infected in human assessed as median efficacy at 2 g administered in adults as single dose2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1146195Antimicrobial activity against Clostridium perfringens ISS 30543 by broth dilution method1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and biological activity of new 2-nitroimidazole derivatives.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID172620The amount of unchanged compound in urine collected at 0-36 hr after treatment1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1743093Half-life of the compound2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Anti-
AID1146199Antimicrobial activity against Trichomonas vaginalis infected in po dosed mouse relative to metronidazole1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and biological activity of new 2-nitroimidazole derivatives.
AID1743040Antigiardial activity against Giardia duodenalis WB (ATCC 30957) incubated for 3 days by fluorescence method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Anti-
AID16038Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
The influence of physicochemical parameters on the biliary excretion of a series of nitroimidazoles.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1193496Thermodynamic equilibrium solubility, log S of the compound in water at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID194141The total 18 hr urinary excretion of the unchanged form of compound in urine was reported as log (percent X 10) of the administered dose by HPLC technique1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID1135605Antimicrobial activity against Entamoeba histolytica NIH 200-mu hepatic forms infected in golden hamster assessed as survival rate administered qd for 5 days measured up to 14 days by microscopic analysis1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
Bisamidines of 2,6-diaminoanthraquinone as antiamebic agents.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1743044Antigiardial activity against Giardia duodenalis Ac1 incubated for 3 days by fluorescence method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Anti-
AID194143The total 18 hr urinary excretion of unchanged compound reported as log (percent X 10) of the administered dose1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID172621The amount of unchanged compound in urine collected at 0-54 hr after treatment1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1743043Antigiardial activity against Giardia duodenalis Ah2 incubated for 3 days by fluorescence method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Anti-
AID1146198Antimicrobial activity against Trichomonas vaginalis infected in po dosed mouse1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Synthesis and biological activity of new 2-nitroimidazole derivatives.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1743042Antigiardial activity against Giardia duodenalis Ah1 incubated for 3 days by fluorescence method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Anti-
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID194146The total 72 hr urinary excretion of unchanged compound reported as log (percent X 10) of the administered dose1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID23681Partition coefficient (logP)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID16039Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
The influence of physicochemical parameters on the biliary excretion of a series of nitroimidazoles.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1193495Thermodynamic equilibrium solubility, log S of the compound in simulated intestinal fluid at pH 6.8 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1743041Antigiardial activity against Giardia duodenalis G1 incubated for 3 days by fluorescence method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Anti-
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1456701Antibacterial activity against Bacteroides fragilis ATCC 23745 after 24 hrs2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases.
AID16040Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
The influence of physicochemical parameters on the biliary excretion of a series of nitroimidazoles.
AID194144The total 36 hr urinary excretion of unchanged compound reported as log (percent X 10) of the administered dose1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Relationship between lipophilic character and urinary excretion of nitroimidazoles and nitrothiazoles in rats.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (922)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990380 (41.21)18.7374
1990's153 (16.59)18.2507
2000's199 (21.58)29.6817
2010's153 (16.59)24.3611
2020's37 (4.01)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 100.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index100.79 (24.57)
Research Supply Index7.21 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index188.39 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (100.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials328 (32.19%)5.53%
Reviews76 (7.46%)6.00%
Case Studies62 (6.08%)4.05%
Observational0 (0.00%)0.25%
Other553 (54.27%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (31)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Oral Tinidazole Treatment of Refractory Trichomonas Vaginitis [NCT05383521]20 participants (Anticipated)Interventional2023-12-01Not yet recruiting
Treatment of Giardia Lamblia Infections in Children: Randomized Open-labeled Trial Comparing Rectal Metronidazole With Oral Tinidazole [NCT02942485]Phase 48 participants (Actual)Interventional2016-12-01Terminated(stopped due to Extremely slow enrollment)
Efficacies of Antimicrobial Susceptibility-Guided Versus Empirical Therapy for Rescue Treatment of Helicobacter Pylori Infection-A Randomized Clinical Trial [NCT03658746]Phase 4420 participants (Actual)Interventional2019-01-01Completed
10-Day Antimicrobial Susceptibility Testing Guided Triple Therapy Versus 14-Day Empirical Tailored Therapy for the First-line Treatment of Helicobacter Pylori Infection-A Randomized Controlled Trail [NCT03571230]Phase 4400 participants (Anticipated)Interventional2018-07-01Not yet recruiting
Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy [NCT04370145]Phase 4160 participants (Actual)Interventional2021-05-01Completed
Testing the Ability of a Microbiome - Focused Intervention to Reduce HIV Susceptibility in Ugandan Men [NCT03412071]125 participants (Anticipated)Interventional2017-12-07Recruiting
A Prospective, Randomized,Controlled Trial on the Effect of Antibiotic Therapy on Endometrial Response in Women With Chronic Endometritis [NCT02648698]120 participants (Actual)Interventional2016-01-10Completed
High Eradication Rate of Helicobacter Pylori Infection With Moxifloxacin-Based Triple Therapy in Comparison With Levofloxacin-Based Sequential Therapy: Randomized Controlled Trials [NCT05863858]Phase 3162 participants (Actual)Interventional2020-06-01Completed
Tinidazole Versus Cefazolin Antibiotic Prophylaxis of Vaginal and Abdominal Hysterectomy [NCT00787553]75 participants (Actual)Interventional2006-07-31Active, not recruiting
Sequential Helicobacter Pylori Eradication Therapy in Myanmar; a Randomized Clinical Trial of Efficacy and Tolerability [NCT04132479]Phase 4313 participants (Actual)Interventional2018-01-01Completed
Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax [NCT00811096]Phase 220 participants (Actual)Interventional2008-11-30Completed
Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection [NCT02711176]Phase 4212 participants (Actual)Interventional2016-09-30Completed
[NCT01070277]100 participants (Anticipated)Interventional2012-03-31Recruiting
Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori: A Pilot Study [NCT05126121]60 participants (Anticipated)Interventional2021-11-20Not yet recruiting
Phase II Randomized, Placebo-Controlled Double-Blind 4-Arm Trial for the Treatment of Non-Gonococcal Urethritis (NGU): Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole) [NCT00322465]Phase 2305 participants (Actual)Interventional2006-11-30Completed
[NCT01481844]Phase 3101 participants (Actual)Interventional2011-11-30Completed
Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study [NCT00510614]Early Phase 137 participants (Actual)Interventional2007-10-31Completed
A Phase III Randomized, Multi-center, Double-blind, Double-dummy, Placebo-controlled Treatment Trial of Bacterial Vaginosis With Tinidazole Oral Tablets. [NCT00229216]Phase 3200 participants (Actual)Interventional2005-01-31Completed
A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis [NCT00324142]Phase 20 participants (Actual)InterventionalWithdrawn(stopped due to Study Terminated Prematurely)
Sequential Therapy Versus Triple Therapy for Helicobacter Pylori Eradication: a Placebo-controlled Trial [NCT00403364]Phase 2/Phase 3300 participants Interventional2003-07-31Completed
Tinidazole for the Treatment of Bacterial Vaginosis [NCT00334633]Phase 4593 participants (Actual)Interventional2004-11-30Completed
Effectiveness of Rifabutin Triple Therapy for First-line and Rescue Treatment of Helicobacter Pylori Infection [NCT04652284]Phase 3300 participants (Anticipated)Interventional2021-05-01Not yet recruiting
Five-day Concomitant Versus 10-day Sequential Therapy for Eradication of Helicobacter Pylori Infection: a Randomized Trial of Levofloxacin-based Regimens [NCT01544517]Phase 3180 participants (Actual)Interventional2011-01-31Completed
Comparison Efficacy of 14-day Concomitant Therapy:Clarithromycin vs.Levofloxacin in Eradication of H.Pylori [NCT03021590]Phase 40 participants (Actual)Interventional2017-06-01Withdrawn(stopped due to No Participants Enrolled)
A Randomised Controlled Trial of Single Dose Tinidazole+Fluconazole Versus Longer Courses of Metronidazole+Clotrimazole in the Management of West African Women With Vaginal Discharge [NCT00313131]Phase 31,524 participants Interventional2004-01-31Completed
Efficacy of Two Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment [NCT02988089]Phase 4480 participants (Anticipated)Interventional2017-04-20Recruiting
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions [NCT01591889]Phase 128 participants (Actual)Interventional2009-09-30Completed
Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment [NCT03139253]Phase 4120 participants (Anticipated)Interventional2017-05-30Not yet recruiting
Helicobacter Pylori First-line Treatment Containing Tetracycline in Patients Allergic to Penicillin:a Prospective Randomized Controlled Study [NCT04122287]Phase 4250 participants (Anticipated)Interventional2019-11-01Recruiting
Helicobacter Pylori Rescue Treatment Containing Tetracycline in Patients Allergic to Penicillin:a Prospective Randomized Controlled Study [NCT04264663]Phase 4250 participants (Anticipated)Interventional2019-11-01Recruiting
Protocol for a Randomised Trial of Observation Versus Chlorambucil After Anti-Helicobacter Therapy in Low Grade Gastric Lymphoma [NCT00003617]Phase 3200 participants (Anticipated)Interventional1995-03-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00322465 (16) [back to overview]Percentage of Participants Achieving Clinical Cure of NGU With (Doxycycline Plus Doxycycline/Tinidazole) Versus (Azithromycin Plus Azithromycin/Tinidazole)
NCT00322465 (16) [back to overview]Percentage of Participants Achieving Clinical Cure of Non-gonococcal Urethritis (NGU) With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole
NCT00322465 (16) [back to overview]Percentage of Participants Achieving Microbiological Cure of Chlamydia Trachomatis With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole
NCT00322465 (16) [back to overview]Percentage of Participants Achieving Microbiological Cure of Mycoplasma Genitalium With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole
NCT00322465 (16) [back to overview]Percentage of Participants Achieving Microbiological Cure of Trichomonas Vaginalis With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole
NCT00322465 (16) [back to overview]Prevalence of Chlamydia Trachomatis in Men With Non-gonococcal Urethritis
NCT00322465 (16) [back to overview]Prevalence of Mycoplasma Genitalium in Men With Non-gonococcal Urethritis
NCT00322465 (16) [back to overview]Prevalence of Trichomonas Vaginalis (Swab or Urine Specimen) in Men With Non-gonococcal Urethritis
NCT00322465 (16) [back to overview]Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Diarrhea
NCT00322465 (16) [back to overview]Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Nausea
NCT00322465 (16) [back to overview]Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting of Abdominal Pain
NCT00322465 (16) [back to overview]Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Stomach Upset
NCT00322465 (16) [back to overview]Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Vomiting
NCT00322465 (16) [back to overview]Clinical, Behavioral, and Demographic Predictors of Chlamydia Trachomatis in Men With Non-gonococcal Urethritis
NCT00322465 (16) [back to overview]Clinical, Behavioral, and Demographic Predictors of Mycoplasma Genitalium in Men With Non-gonococcal Urethritis
NCT00322465 (16) [back to overview]Clinical, Behavioral, and Demographic Predictors of Trichomonas Vaginalis in Men With Non-gonococcal Urethritis
NCT00334633 (2) [back to overview]Cure of Bacterial Vaginosis
NCT00334633 (2) [back to overview]Recurrence of BV
NCT02648698 (1) [back to overview]The Conversion Rate of CE (From Positive to Negative)
NCT02942485 (3) [back to overview]Clinical Recovery
NCT02942485 (3) [back to overview]Number of Participants With Negative G.Lamblia Antigen Test
NCT02942485 (3) [back to overview]Number of Participants With Side-effects

Percentage of Participants Achieving Clinical Cure of NGU With (Doxycycline Plus Doxycycline/Tinidazole) Versus (Azithromycin Plus Azithromycin/Tinidazole)

"Clinical Cure of NGU: Did not meet criteria for clinical failure at last evaluable follow-up visit.~Clinical Failure at first follow-up: [Persistent symptoms AND >= 5 PMNs per 3-5 oil immersion fields (regardless of urethral discharge)] OR Persistent urethral discharge on exam (regardless of symptoms or number of PMNs).~Clinical Failure at second follow-up: >= 5 PMNs per 3-5 oil immersion fields (regardless of symptoms or presence of urethral discharge) OR Persistent urethral discharge on exam (regardless of symptoms or number of PMNs)" (NCT00322465)
Timeframe: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)

InterventionPercentage of participants (Number)
Doxycycline + (Doxycycline + Tinidazole)49
Azithromycin + (Azithromycin + Tinidazole)44

[back to top]

Percentage of Participants Achieving Clinical Cure of Non-gonococcal Urethritis (NGU) With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole

"Clinical Cure of NGU: Did not meet criteria for clinical failure at last evaluable follow-up visit.~Clinical Failure at first follow-up: [Persistent symptoms AND >= 5 polymorphonuclear leukocytes (PMNs) per 3-5 oil immersion fields (regardless of urethral discharge)] OR Persistent urethral discharge on exam (regardless of symptoms or number of PMNs).~Clinical Failure at second follow-up: >= 5 PMNs per 3-5 oil immersion fields (regardless of symptoms or presence of urethral discharge) OR Persistent urethral discharge on exam (regardless of symptoms or number of PMNs)" (NCT00322465)
Timeframe: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)

InterventionPercentage of participants (Number)
Doxycycline47
Doxycycline + Tinidazole51
Azithromycin39
Azithromycin + Tinidazole48

[back to top]

Percentage of Participants Achieving Microbiological Cure of Chlamydia Trachomatis With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole

Microbiological cure of Chlamydia trachomatis refers to the percentage of men with NGU who were negative for Chlamydia trachomatis at the last available result and had been positive for Chlamydia trachomatis at baseline. (NCT00322465)
Timeframe: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)

InterventionPercentage of participants (Number)
Doxycycline89
Doxycycline + Tinidazole75
Azithromycin66
Azithromycin + Tinidazole61

[back to top]

Percentage of Participants Achieving Microbiological Cure of Mycoplasma Genitalium With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole

Microbiological Cure of Mycoplasma Genitalium refers to the percentage of men with NGU who were negative for Mycoplasma Genitalium at the last available result and had been positive for Mycoplasma Genitalium at baseline. (NCT00322465)
Timeframe: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)

InterventionPercentage of participants (Number)
Doxycycline23
Doxycycline + Tinidazole32
Azithromycin52
Azithromycin + Tinidazole68

[back to top]

Percentage of Participants Achieving Microbiological Cure of Trichomonas Vaginalis With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole

Microbiological cure of Trichomonas vaginalis refers to the percentage of men with NGU who were negative for Trichomonas vaginalis (swab and urine specimens) at the last available result and had been positive for Trichomonas vaginalis at baseline (swab or urine specimen). (NCT00322465)
Timeframe: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)

InterventionPercentage of participants (Number)
Doxycycline55
Doxycycline + Tinidazole75
Azithromycin56
Azithromycin + Tinidazole50

[back to top]

Prevalence of Chlamydia Trachomatis in Men With Non-gonococcal Urethritis

Percentage of men with non-gonococcal urethritis that had a positive result for Chlamydia trachomatis at baseline (enrollment) (NCT00322465)
Timeframe: Baseline (enrollment visit)

InterventionPercentage of participants (Number)
Doxycycline50
Doxycycline + Tinidazole38
Azithromycin38
Azithromycin + Tinidazole46

[back to top]

Prevalence of Mycoplasma Genitalium in Men With Non-gonococcal Urethritis

Percentage of men with non-gonococcal urethritis that had a positive result for Mycoplasma genitalium at baseline (enrollment) (NCT00322465)
Timeframe: Baseline (enrollment)

InterventionPercentage of participants (Number)
Doxycycline29
Doxycycline + Tinidazole30
Azithromycin32
Azithromycin + Tinidazole32

[back to top]

Prevalence of Trichomonas Vaginalis (Swab or Urine Specimen) in Men With Non-gonococcal Urethritis

Percentage of men with non-gonococcal urethritis that had a positive result for Trichomonas vaginalis from a urethral swab or urine specimen at baseline (enrollment) (NCT00322465)
Timeframe: Baseline (enrollment visit)

InterventionPercentage of participants (Number)
Doxycycline14
Doxycycline + Tinidazole16
Azithromycin12
Azithromycin + Tinidazole10

[back to top]

Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Diarrhea

At all study visits, unsolicited adverse events were recorded. Nausea, Vomiting, Abdominal pain, and Diarrhea were recorded using National Cancer Institute Common Toxicity Criteria (Version 3.0). (NCT00322465)
Timeframe: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)

InterventionParticipants (Number)
Doxycycline0
Doxycycline + Tinidazole3
Azithromycin3
Azithromycin + Tinidazole7

[back to top]

Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Nausea

At all study visits, unsolicited adverse events were recorded. Nausea, Vomiting, Abdominal pain, and Diarrhea were recorded using National Cancer Institute Common Toxicity Criteria (Version 3.0). (NCT00322465)
Timeframe: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)

InterventionParticipants (Number)
Doxycycline3
Doxycycline + Tinidazole4
Azithromycin0
Azithromycin + Tinidazole4

[back to top]

Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting of Abdominal Pain

At all study visits, unsolicited adverse events were recorded. Nausea, Vomiting, Abdominal pain, and Diarrhea were recorded using National Cancer Institute Common Toxicity Criteria (Version 3.0). (NCT00322465)
Timeframe: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)

InterventionParticipants (Number)
Doxycycline6
Doxycycline + Tinidazole5
Azithromycin3
Azithromycin + Tinidazole5

[back to top]

Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Stomach Upset

At all study visits, unsolicited adverse events were recorded. (NCT00322465)
Timeframe: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)

InterventionParticipants (Number)
Doxycycline1
Doxycycline + Tinidazole1
Azithromycin1
Azithromycin + Tinidazole0

[back to top]

Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Vomiting

At all study visits, unsolicited adverse events were recorded. Nausea, Vomiting, Abdominal pain, and Diarrhea were recorded using National Cancer Institute Common Toxicity Criteria (Version 3.0). (NCT00322465)
Timeframe: First follow-up visit (Day 15-19), second follow-up visit (Day 35-45)

InterventionParticipants (Number)
Doxycycline4
Doxycycline + Tinidazole2
Azithromycin0
Azithromycin + Tinidazole0

[back to top]

Clinical, Behavioral, and Demographic Predictors of Chlamydia Trachomatis in Men With Non-gonococcal Urethritis

Clinical, behavioral, and demographic variables considered were discharge amount and appearance; condom use last sex; new recent partner; number of partners and new partners in last 30 days as well as last 3 months; number of times vaginal sex, oral sex, or anal sex in past 30 days; always/almost always used condom in last 3 months. (NCT00322465)
Timeframe: Baseline (enrollment visit)

InterventionParticipants (Number)
Positive for Chlamydia Trachomatis at BaselineNegative for Chlamydia Trachomatis at Baseline
All Participants Analyzed128162

[back to top]

Clinical, Behavioral, and Demographic Predictors of Mycoplasma Genitalium in Men With Non-gonococcal Urethritis

Logistic multiple regression with independent variable selection based on single variable models with p<0.10. Participants positive at enrollment for Mycoplasma genitalium from urine specimen. Potential variables: discharge amount and appearance; condom use last sex; new recent partner, number of partners and new partners in last 30 days and last 3 months; number of times vaginal sex, oral sex, or anal sex in last 30 days; always/almost always used condom last 3 months. (NCT00322465)
Timeframe: Baseline (enrollment visit)

InterventionParticipants (Number)
Positive for Mycoplasma Genitalium at BaselineNegative for Mycoplasma Genitalium at Baseline
All Participants Analyzed90202

[back to top]

Clinical, Behavioral, and Demographic Predictors of Trichomonas Vaginalis in Men With Non-gonococcal Urethritis

Trichomonas vaginalis was determined from urethral swab or urine specimen. Clinical, behavioral, and demographic predictors considered included discharge amount and appearance; condom use last sex; new recent partner; number of partners and new partners in last 30 days and last 3 months; number of times vaginal sex, oral sex, or anal sex in last 30 days; always/almost always used condom in last 3 months. (NCT00322465)
Timeframe: Baseline (enrollment visit)

InterventionParticipants (Number)
Positive for Trichomonas Vaginalis at BaselineNegative for Trichomonas Vaginalis at Baseline
All Participants Analyzed38253

[back to top]

Cure of Bacterial Vaginosis

resolution of Amsel criteria for bacterial vaginosis (NCT00334633)
Timeframe: one month

Interventionparticipants (Number)
Metronidazole75
Tinidazole 500 mg73
Tinidazole 1 gm77

[back to top]

Recurrence of BV

(NCT00334633)
Timeframe: baseline to 4 weeks

InterventionParticipants (Count of Participants)
Control42
Tinidazole 50045
Tinidazole 1 gm37

[back to top]

The Conversion Rate of CE (From Positive to Negative)

"Subjects in antibiotic group underwent a second-look hysteroscopy and repeat endometrial biopsy for histopathological CD138 immunohistochemical examination 2-4 weeks after completion of antibiotic treatment and in the follicular phase of the following menstrual cycle. Subjects in control group underwent a second-look hysteroscopy and repeat endometrial biopsy for histopathological CD138 immunohistochemical examination ~4 weeks after recruitment in the follicular phase of the following menstrual cycle.~The biopsies were graded as negative for CE if there was less than one plasma cell identified per 10 high-power fields (HPFs) and positive when there was one or more plasma cell identified per 10 HPFs.~To compare the cure rate (From positive to negative) of CE in women who received antibiotic therapy (treatment group) with the spontaneous cure rate in those who did not receive antibiotic therapy (control group)," (NCT02648698)
Timeframe: 1-6 months

InterventionPercentage of participants (Number)
Antibiotic Group89.8
Control Group12.7

[back to top]

Clinical Recovery

Clinical recovery was defined as the resolution of symptoms by day 10 post-treatment, assessed using a structured questionnaire by interviewing the parents/caregivers. (NCT02942485)
Timeframe: 10 days

InterventionParticipants (Count of Participants)
Metronidazole4
Tinidazole0

[back to top]

Number of Participants With Negative G.Lamblia Antigen Test

Microbiological recovery was defined as negative G.lamblia antigen test from fecal samples collected on day 10 post-treatment. (NCT02942485)
Timeframe: 10 days

InterventionParticipants (Count of Participants)
Metronidazole5
Tinidazole1

[back to top]

Number of Participants With Side-effects

Will be assessed using structured questionnaire by interviewing parents/caregivers. (NCT02942485)
Timeframe: 10 days

InterventionParticipants (Count of Participants)
Metronidazole1
Tinidazole0

[back to top]